Olmesartán/Amlodipino/Hidroclorotiazida Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium entry into vascular smooth‑muscle cells, causing arterial dilation. Hydrochlorothiazide promotes sodium and water excretion in the kidney, decreasing plasma volume. The combined actions reduce peripheral resistance and intravascular volume, providing an additive antihypertensive effect.

The appropriate dose of Olmesartán/Amlodipino/Hidroclorotiazida Krka is determined by the prescribing healthcare professional based on the patient’s blood‑pressure goals, renal function, and concomitant therapies. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Olmesartan is contraindicated in the second and third trimesters of pregnancy because of the risk of fetal toxicity. The combination is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit outweighs the risk and it is prescribed by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with single‑agent therapy, the olmesartan/amlodipine/hydrochlorothiazide combo offers three complementary mechanisms—RAAS blockade, calcium‑channel mediated vasodilation, and diuresis—allowing more robust blood‑pressure control in patients who need multiple agents. It can simplify regimens and improve adherence versus taking three separate tablets, while maintaining a safety profile similar to the individual components.

Store the tablets at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water. Do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events include severe hypotension, electrolyte disturbances such as hyper‑ or hypokalaemia, acute kidney injury, and angioedema that can affect the airway. Patients should seek immediate medical attention if they experience fainting, swelling of the face or throat, sudden loss of kidney function, or marked changes in blood‑pressure readings.

The combination is contraindicated in patients with known hypersensitivity to any of its components, in those with severe hepatic impairment, and in pregnant women during the second and third trimesters. It should also be avoided in individuals with severe renal artery stenosis or in patients taking aliskiren who have diabetes.